Low-dose XXXX effect on somatic growth.

@entity1 @entity251 @entity1184 @entity2689 @entity21668
Low-dose @entity251 has been found to preserve the growth potential of hypogonadal @entity1 requiring anabolic or androgenic therapy. Five @entity1 with @entity2689 were treated when their chronologic ages were 13 to 14 years and their bone ages were 10.6 to 12.75 years; six hypogonadal @entity1 were treated when their chronologic ages were 11 to 15 years and their bone ages were 10.9 to 14.2 years. Depot @entity251 was given as an anabolic agent in an average dose of 28 mg/m2/mo for 6 months to the @entity1 with @entity2689 and was given to initiate puberty in an average dose of 44 mg/m2/mo for 6 months to the hypogonadal @entity1 . Growth rate doubled on these doses of @entity251 , and bone age did not advance disproportionately. Consequently, height potential was preserved. Pubic hair advanced one Tanner stage during the 6-month treatment. @entity1184 was observed in only one of the five @entity1 with @entity2689 and regressed when @entity251 therapy was discontinued. Four hypogonadal @entity1 were continued on low-dose @entity251 until their bone ages passed 14 years of age and their growth rate waned. Then, the @entity251 dosage was increased in increments to 100 to 200 mg/m2/mo. This group reached a height of 100.3 +/- 0.8% of the height initially predicted. In addition, all attained an adult height at least 15 percentiles greater than that before therapy. These studies indicate that @entity251 in very low doses resembles " @entity21668 " in that growth is stimulated without an inordinate androgenic effect. Furthermore, these studies show that institution of low-dose therapy in the early teenage years stimulates pubertal growth normally without loss of height potential.
